Type to search

Samuel A. Goldlust

Share

Cancers and their treatments can cause neurologic symptoms, such as seizures, stroke, neuropathy, and cognitive effects—even without directly invading the nervous system. Samuel Goldlust, MD, is a neuro-oncologist who specializes in the treatment of brain tumors and the neurological issues that arise from multimodality cancer therapies.

Dr. Goldlust pursued his undergraduate studies in chemistry at Miami University, where he graduated Summa Cum Laude and was inducted into Phi Beta Kappa. He received his medical doctorate at The Ohio State University with distinction in biomedical research, followed by a residency in neurology at New York University Hospitals. After serving as chief resident, Dr. Goldlust went on to a fellowship in neurological oncology under the mentorship of Dr. Jerome Posner at Memorial Sloan Kettering Cancer Center, where he was elected to serve as chief fellow in his final year of training.

He joined the faculty of John Theurer Cancer Center (JTCC) in 2011, and together with neurosurgeon George Kaptain, MD, he founded the Brain and Spine Institute. In the years to follow, he has helped bring JTCC to the forefront of brain tumor clinical care and research, having served as principal investigator on 25 studies of novel therapeutics—primarily for glioblastoma, and several as the national lead investigator. He is widely published in the neuro-oncology medical literature, including recent practice-changing contributions to Lancet Oncology, Neuro-Oncology, and the Journal of Clinical Oncology.

Moreover, Dr. Goldlust serves as the JTCC lead investigator for ALLIANCE (the National Cancer Institute’s premier clinical trial collaborative) and on the Clinical Research Committee of Georgetown Lombardi Comprehensive Cancer Center. He has been recognized by the End Brain Cancer Initiative for his compassion and his dedication to brain tumor patients.

Samuel A. Goldlust
Medical Director of Neuro-Oncology
John Theurer Cancer Center

Samuel A. Goldlust

Cancers and their treatments can cause neurologic symptoms, such as seizures, stroke, neuropathy, and cognitive effects—even without directly invading the nervous system. Samuel Goldlust, MD, is a neuro-oncologist who specializes in the treatment of brain tumors and the neurological issues that arise from multimodality cancer therapies.

Dr. Goldlust pursued his undergraduate studies in chemistry at Miami University, where he graduated Summa Cum Laude and was inducted into Phi Beta Kappa. He received his medical doctorate at The Ohio State University with distinction in biomedical research, followed by a residency in neurology at New York University Hospitals. After serving as chief resident, Dr. Goldlust went on to a fellowship in neurological oncology under the mentorship of Dr. Jerome Posner at Memorial Sloan Kettering Cancer Center, where he was elected to serve as chief fellow in his final year of training.

He joined the faculty of John Theurer Cancer Center (JTCC) in 2011, and together with neurosurgeon George Kaptain, MD, he founded the Brain and Spine Institute. In the years to follow, he has helped bring JTCC to the forefront of brain tumor clinical care and research, having served as principal investigator on 25 studies of novel therapeutics—primarily for glioblastoma, and several as the national lead investigator. He is widely published in the neuro-oncology medical literature, including recent practice-changing contributions to Lancet Oncology, Neuro-Oncology, and the Journal of Clinical Oncology.

Moreover, Dr. Goldlust serves as the JTCC lead investigator for ALLIANCE (the National Cancer Institute’s premier clinical trial collaborative) and on the Clinical Research Committee of Georgetown Lombardi Comprehensive Cancer Center. He has been recognized by the End Brain Cancer Initiative for his compassion and his dedication to brain tumor patients.

Posts Featuring Samuel A. Goldlust


Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: addcslashes() expects parameter 1 to be string, array given in /home/customer/www/pharmtechfocus.com/public_html/wp-includes/class-wpdb.php on line 1562
John Theurer Cancer Center Treats First Patient in U.S. with Investigational New Treatment for Brain Cancer | Pharmtech Focus

John Theurer Cancer Center Treats First Patient in U.S. with Investigational New Treatment for Brain Cancer